ANAPTYSBIO, INC. Income (Loss) from Continuing Operations before Income Taxes, Domestic
ANAPTYSBIO, INC. (ANAB) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$5.09 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-09-21
- ANAPTYSBIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $162.28M, a 423.47% increase from fiscal 2024.
- ANAPTYSBIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $31.00M.
- ANAPTYSBIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$163.58M.
- ANAPTYSBIO, INC. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$128.65M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 6 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|---|
| 2026-06-30 | -$5.09M 10-KT · filed 2026-09-21 | ||
| 2025-12-31 | $162.28M 10-KT · filed 2026-09-21 | -$13.07M 10-K · filed 2026-03-03 | |
| 2024-12-31 | $31.00M 10-KT · filed 2026-09-21 | -$145.37M 10-K · filed 2025-02-27 | |
| 2023-12-31 | -$163.58M 10-K · filed 2026-03-03 | ||
| 2022-12-31 | -$128.65M 10-K · filed 2025-02-27 | ||
| 2021-12-31 | -$57.74M 10-K · filed 2024-03-11 | ||
| 2020-12-31 | -$19.83M 10-K · filed 2023-03-01 | ||
| 2019-12-31 | -$97.19M 10-K · filed 2022-03-07 | ||
| 2018-12-31 | -$61.19M 10-K · filed 2021-02-25 | ||
| 2017-12-31 | -$27.49M 10-K · filed 2020-03-02 | ||
| 2016-12-31 | -$632.00K 10-K · filed 2019-02-28 | ||
| 2015-12-31 | $1.72M 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |